ClinicalTrials.gg
Sign In
Drug

Safimaltib clinical trials

Also written JNJ-67856633.

studies test it
4
open now
1
in phase 3
0
first study started
2019

How each study uses safimaltib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the safimaltib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorisations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

safimaltib
1

Development codes

JNJ-67856633
4

Studies by the year they started

4 studies that test it; most in 2021 (2)

Studies that test safimaltib, by start year
YearStudies
20191
20212
20241

By phase

A phase 1/2 study counts in both.

Phase 1
4

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Leukemia, Lymphocytic, Chronic, B-Cell
2
Lymphoma, Non-Hodgkin
1
Leukemia, Myeloid, Acute
1

Who runs them

Industry 4 · Other 0

Janssen Research & Development, LLC (4)

Often tested with

Tested in the same studies.

JNJ-64264681 (2) · Rezetamig (1) · Ibrutinib (1) · DHODH Inhibitor JNJ-74856665 (1) · Anti-TMEFF2/Anti-CD3 Bispecific Antibody JNJ-70218902 (1) · JNJ-64619178 (1) · Anti-CD79b/CD20/CD3 Trispecific Antibody JNJ-80948543 (1) · JNJ-87801493 (1)

Studies

Open first, then newest update. How each study uses safimaltib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 4

Codes

What other systems call safimaltib · ClinicalTrials.gg INT017155

  • UNII (FDA) L9790S42AISAFIMALTIBOne source FDA
  • NCI Thesaurus C160147SafimaltibOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.